Sep 2026· Gut Medicine· Vol 2, pp. 116-120· 0 citations· 14 references
TL;DR
Insight is provided into the potential use of tumorigenesis models and their key metrics, drawing on advances in gut medicine, which hold promise for future early diagnosis and clinical decision‐making.
Abstract
Reproducing tumor biology in vivo using three‐dimensional organoids remains a debated topic in the cancer organoid field, despite the new FDA framework for evaluating cancer drugs with organoid models. Compared with patient‐derived organoids (PDOs), which offer a humanized model for testing cancer therapies, organoids derived from normal stem cells primarily focus on elucidating mechanisms of tumor development and early prevention. To date, studies modeling colon cancer have successfully identified suitable pathways for organoid‐based tumorigenesis. In this perspective review, we provide insights into the potential use of tumorigenesis models and their key metrics, drawing on advances in gut medicine. Overall, developing personalized tumorigenic organoid models holds promise for future early diagnosis and clinical decision‐making.
Patient‐derived organoids (PDOs) have emerged as an effective experimental platform for bridging the long‐standing gap between traditional in vitro cancer models and the biological complexity of actual tumors. These three‐dimensional cultures (3D), derived directly from patient tissues, preserve essential architectural...
Abdullah Jabri, Mohamed Alsharif, Abdulaziz Mhannayeh et al.· Cell Biochemistry and Functi...· 0 citations
This review will synthesize emerging findings, define key technological and biological gaps, and outline future directions for integrating hPSC-based modeling into precision oncology and translational cancer research.
Chih-Wei Chu, Yen-Tzu Chang, Candise Tat et al.· Trends in Molecular Medicine· 0 citations
Ovarian cancer (OC) is the deadliest gynecological malignancy which continues to impose a significant challenge in the field of oncology research due to its rapid metastasis, inter and intra-tumor heterogeneity, and treatment resistance. Personalized medicine for OC is still under development where patient-derived orga...
A. Nikam, Gyamcho Tshering Bhutia, Sinjini Sarkar· Frontiers in Oncology· 0 citations
Prostate cancer ranks among the most prevalent male malignancies worldwide, with castration-resistant prostate cancer (CRPC) and drug resistance representing major clinical challenges. Conventional preclinical models fail to faithfully recapitulate tumor heterogeneity and the tumor microenvironment (TME). Patient-deriv...
Jing-Zhen Zhu, Sheng Wang, Fu-Rong Du et al.· Frontiers in Oncology· 0 citations
This systematic review synthesized data from 13 studies evaluating the feasibility, histological fidelity, and clinical concordance of ovarian cancer patient-derived organoids to suggest PDOs represent a robust platform for functional drug screening within a clinically actionable 21-day window.
Reem Alzahrani, Maha Ali Alghadmi· Cancer Chemotherapy and Phar...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.